Boehringer Ingelheim and 3T Biosciences to develop next-generation cancer immunotherapies
Boehringer Ingelheim and 3T Biosciences have entered into a strategic collaboration and licensing agreement to…
Boehringer Ingelheim and 3T Biosciences have entered into a strategic collaboration and licensing agreement to…
More than half of patients treated for psoriasis with an intravenous injection showed no visible…
A joint venture to create the next generation of antimicrobials, along with actionable diagnostics to…
Current treatments for cystic fibrosis are not suitable for all patients and have a limited…
The FDA recently approved an antibody-drug conjugate drug from ADC Therapeutics as a treatment for…
The German giant Boehringer Ingelheim has acquired the Swiss company AMAL Therapeutics and its cancer…
Boehringer Ingelheim is paying €210M to acquire all the remaining shares of ViraTherapeutics, an Austrian…
OSE Immunotherapeutics could receive up to €1.1Bn from its new partner Boehringer Ingelheim, which has…
Boehringer Ingelheim has ditched its Alzheimer's drug after it failed to meet the endpoints of…
Boehringer Ingelheim has committed to continue helping young companies grow by doubling the size of…
Santa Claus is not the only busy one in the weeks leading up to Christmas…
Boehringer Ingelheim's fight against liver disease is taking shape, having agreed on a partnership with…